CoChat
Sign Up
Cited by 18Antibiotic Resistance in BacteriaUrinary Tract Infections ManagementAntibiotic Use and Resistance

Occurrence and distribution of extended-spectrum β-lactamase in clinical Escherichia coli isolates at Ho Teaching Hospital in Ghana.

Open access
G. Deku, John, O. Duedu, Kwabena, Ativi, Emmanuel, E. Kpene, Godsway, K. Feglo, Patrick·2021·Ghana Medical Journal
DOI 10.4314/gmj.v55i4.11PMC PMC9334966
Open this paper in CoChat — free accountOpen PDF

Abstract

Objective: isolates in Ho Teaching Hospital, Ghana. Design: A cross-sectional study. Setting: A single centre study was conducted at Ho Teaching Hospital of Ghana. Participants: Patients who visited Ho Teaching Hospital Laboratory with the request for culture and susceptibility testing. Main outcome measure: were isolated, and Extended-Spectrum β-Lactamase genes were detected. Results: Of the 135 isolates, 56(41.5%,95% CI: 33.1% - 50.3%) were ESBL producers. More males, 14(58.3%), produced ESBL than females, 42(37.8%). The ESBL prevalence was highest among the elderly who were 80 years and above 3(100.0%), with the least prevalence among patients within 50-59 years and 0-9 years age bracket, representing 4(25.0%) and 3(27.3%), respectively. The total prevalence of ESBL was marginally higher among out-patients (41.8% 95% CI: 31.9% - 52.2%) compared to in-patients [40.5% 95% CI: 24.8% - 57.9]. BlaTEM-1 was the predominant ESBL genotype obtained from 83.9% (47/56) of the confirmed ESBL producing isolates, with the least being TOHO-1 4(7.1%). The co-existence of 2 different ESBL genes occurred in 19(33.9%) of the isolates. The single and quadruple carriage were 16(28.6%) and 3(5.4%), respectively. The highest co-existence of the ESBL genotypes was recorded for blaTEM-1 and blaCTXM-1 15(26.8%), followed by blaTEM-1, blaCTXM-1 and blaSHV-73 [12(21.4%)]. Conclusion: isolates with multiple resistant gene carriage is a threat to healthcare in the study area. Funding: This research received no external funding.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4314/gmj.v55i4.11

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In six human studies, E. coli exhibited MDR, with prevalence ranging from 41.5% to 99.6%.

    “In six “human studies”, E. coli exhibited MDR, with the prevalence ranging from 41.5% to 99.6% [18,23,27,34,36,41].”

    From A Systematic Review on Antimicrobial Resistance in Ghana from a One Health Perspective (2024) · cites this paper as [27]

    The Results report 41.5% among clinical E. coli isolates, matching the lower endpoint of the cited range. But that figure is the prevalence of ESBL production, not a reported prevalence of multidrug resistance (MDR). This paper does not establish the 99.6% endpoint or the range across six studies. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 34

  1. [1]Kiratisin P Apisarnthanarak A Laesripa C Saifon P Molecular characterization and epidemiology of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic Antimicrob Agents Chemother 2008 52 8 2818 2824 18505851 PMC2493136
  2. [2]Cheng J Ye Y WANG Yy Li H Li X LI Jb Phenotypic and molecular characterization of 5 novel CTX-M enzymes carried by Klebsiella pneumoniae and Escherichia coli 1 Acta Pharmacol Sin 2008 29 2 217 225 18215351
  3. [3]Shashwati N Kiran T Dhanvijay A Study of extended spectrum β-lactamase producing Enterobacteriaceae and antibiotic coresistance in a tertiary care teaching hospital J Nat Sci Biol Med 2014 5 1 30 24678193 PMC3961948
  4. [4]Colodner R Rock W Chazan B Keller N Guy N Sakran W Raz R Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients Eur J Clin Microbiol Infect Dis 2004 23 3 163 167 14986159
  5. [5]Nakai H Hagihara M Kato H Hirai J Nishiyama N Koizumi Y Sakanashi D Suematsu H Yamagishi Y Mikamo H Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae J Infect Chemother 2016 22 5 319 326 26968486
  6. [6]Abayneh M Tesfaw G Abdissa A Isolation of extended-spectrum β-lactamase-(ESBL-) producing Escherichia coli and Klebsiella pneumoniae from patients with community-onset urinary tract infections in Jimma University Specialized Hospital, Southwest Ethiopia Can J Infect Dis Med Microbiol 2018 2018 PMC6311771 30651898
  7. [7]Sianipar O Asmara W Dwiprahasto I Mulyono B Mortality risk of bloodstream infection caused by either Escherichia coli or Klebsiella pneumoniae producing extended-spectrum β-lactamase: a prospective cohort study BMC Res Notes 2019 12 1 1 7 31675991 PMC6824086
  8. [8]Melzer M Petersen I Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli J Infect 2007 55 3 254 259 17574678
  9. [9]Tufa TB Fuchs A Tufa TB Stotter L Kaasch AJ Feld T Haussinger D Mackenzie CR High rate of extended-spectrum beta-lactamase-producing gramnegative infections and associated mortality in Ethiopia: a systematic review and meta-analysis Antimicrob Resist Infect Control 2020 9 1 1 10 32771059 PMC7414654
  10. [10]Pitout JD Nordmann P Laupland KB Poirel L Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community J Antimicrob Chemother 2005 56 1 52 59 15917288
  11. [11]Quan J Zhao D Liu L Chen Y Zhou J Jiang Y Du X Zhou Z Akova M Yu Y High prevalence of ESBL-producing Escherichia coli and Klebsiella pneumoniae in community-onset bloodstream infections in China J Antimicrob Chemother 2016 72 1 273 280 27624571
  12. [12]Singh N Pattnaik D Neogi DK Jena J Mallick B Prevalence of ESBL in Escherichia coli isolates among ICU patients in a tertiary care hospital J Clin Diagn Res 2016 10 9 PMC5071933 27790433
  13. [14]Mashwal FA El Safi SH George SK Adam AA Jebakumar AZ Incidence and molecular characterization of the extended spectrum beta lactamase-producing Escherichia coli isolated from urinary tract infections in Eastern Saudi Arabia Saudi Med J 2017 38 8 811 28762433 PMC5556297
  14. [15]Shakya P Shrestha D Maharjan E Sharma VK Paudyal R ESBL production among E. coli and Klebsiella spp. causing urinary tract infection: a hospital based study Open Microbiol J 2017 11 23 28553414 PMC5427687
  15. [16]Sharma M Pathak S Srivastava P Prevalence and antibiogram of Extended Spectrum β-Lactamase (ESBL) producing Gram negative bacilli and further molecular characterization of ESBL producing Escherichia coli and Klebsiella spp J Clin Diagn Res 2013 7 10 2173 24298468 PMC3843424
  16. [17]Hertz FB Jansaker F Okon KO Abdulmumin IS Onah JO Ladan J Knudsen JDJM ESBL-production in Escherichia coli and Klebsiella pneumoniae isolates from Nigeria Microbiologyopen 2019 8 9 e00816 30801967 PMC6741120
  17. [18]Anago E Ayi-Fanou L Akpovi CD Hounkpe WB Tchibozo MA-D Bankole HS Sanni A Antibiotic resistance and genotype of beta-lactamase producing Escherichia coli in nosocomial infections in Cotonou, Benin Ann Clin Microbiol Antimicrob 2015 14 1 1 6 25595314 PMC4304606
  18. [19]Musicha P Feasey NA Cain AK Kallonen T Chaguza C Peno C Khonga M Thompson S Gray KJ Mather A Genomic landscape of extended-spectrum β-lactamase resistance in Escherichia coli from an urban African setting J Antimicrob Chemother 2017 72 6 1602 1609 28333330 PMC5437524
  19. [20]Abujnah AA Zorgani A Sabri MA El-Mohammady H Khalek RA Ghenghesh KS Multidrug resistance and extended-spectrum β-lactamases genes among0 Escherichia coli from patients with urinary tract infections in Northwestern Libya Libyan J Med 2015 10 1 PMC4315781 25651907
  20. [21]Hassuna NA Khairalla AS Farahat EM Hammad AM Abdel-Fattah M Molecular characterization of Extended-spectrum β lactamase-producing E. coli recovered from community-acquired urinary tract infections in Upper Egypt Sci Rep 2020 10 1 1 8 32066805 PMC7026060
  21. [24]CSLI Performance Standards for Antimicrobial Susceptibility Testing 2018 M100, 28th Edition, 940 West Valley Road, Suite 1400, Wayne, PA 19807
  22. [26]Pitout JD Hossain A Hanson ND Phenotypic and molecular detection of CTX-M-β-lactamases produced by Escherichia coli and Klebsiella spp Clin Microbiol Infect 2004 42 12 5715 5721 PMC535227 15583304
  23. [27]Wang XW Yao Zhou Ying Wang Zheng Wang Yang Zhang Suxia Data_Sheet_1_Emergence of Colistin Resistance Gene mcr-8 and Its Variant in Raoultella 2019 ornithinolytica.doc. Frontiers. Dataset 10.3389/fmicb.2019.00228.s001 PMC6384272 30828324 · DOI
  24. [28]Mahamat OO Lounnas M Hide M Dumont Y Tidjani A Kamougam K Abderrahmane M Benavides J Solassol J Banuls A-L High prevalence and characterization of extended-spectrum s-lactamase producing Enterobacteriaceae in Chadian hospitals BMC Infect Dis 2019 19 1 1 7 30819135 PMC6396450
  25. [30]Sangare SA Maiga AI Guindo I Maiga A Camara N Dicko OA Diallo S Bougoudogo F Armand-Lefevre L Andremont A Prevalence of ESBL-producing Enterobacteriaceae isolated from blood cultures in Mali J Infect Dev Ctries 2016 10 10 1059 1064 27801367
  26. [33]Aworh MK Kwaga J Okolocha E Harden L Hull D Hendriksen RS Thakur S Extended-spectrum slactamase-producing Escherichia coli among humans, chickens and poultry environments in Abuja, Nigeria One Health Outlook 2020 2 1 11 33829130 PMC7993457
  27. [35]Paterson DL Bonomo RA Extended-spectrum β-lactamases: a clinical update Clin Microbiol Rev 2005 18 4 657 686 16223952 PMC1265908
  28. [37]Mathers AJ Peirano G Pitout JD The role of epidemic resistance plasmids and international highrisk clones in the spread of multidrug-resistant Enterobacteriaceae Clin Microbiol Rev 2015 28 3 565 591 25926236 PMC4405625
  29. [38]Teklu DS Negeri AA Legese MH Bedada TL Woldemariam HK Tullu KD Extended-spectrum beta-lactamase production and multi-drug resistance among Enterobacteriaceae isolated in Addis Ababa, Ethiopia Antimicrob Resist Infect Control 2019 8 1 39 30815254 PMC6377715
  30. [39]Abrar S Ain NU Liaqat H Hussain S Rasheed F Riaz S Distribution of bla CTX− M, bla TEM, bla SHV and bla OXA genes in Extended-spectrum-β-lactamase-producing Clinical isolates: A three-year multi-center study from Lahore, Pakistan Antimicrob Resist Infect Control 2019 8 1 80 31139363 PMC6530043
  31. [40]Fernandes R Amador P Oliveira C Prudencio C Molecular characterization of ESBL-producing Enterobacteriaceae in northern Portugal Sci World J 2014 2014 PMC3950362 24701189
  32. [42]Gaddar N Anastasiadis E Halimeh R Ghaddar A Matar GM Abou Fayad A Sherri N Dhar R AlFouzan W Yusef H Phenotypic and Genotypic Characterization of Extended-Spectrum Beta-Lactamases Produced by Escherichia coli Colonizing Pregnant Women Infect Dis Obstet Gynecol 2020 2020 PMC7168714 32327921
  33. [43]Al-Garni SM Ghonaim MM Ahmed MMM Al-Ghamdi AS Ganai FA Risk factors and molecular features of extended-spectrum beta-lactamase producing bacteria at southwest of Saudi Arabia Saudi Med J 2018 39 12 1186 30520499 PMC6344649
  34. [44]Leimbach A Hacker J Dobrindt U E. coli as an allrounder: the thin line between commensalism and pathogenicity Curr Top Microbiol Immunol 2013 3 32 23340801

Cited by

Sorted by citations

Authors
G. Deku, J., O. Duedu, K., Ativi, E., E. Kpene, G., & K. Feglo, P.
Affiliations
University of Health and Allied Sciences (GH)
ORCID
Ativi, Emmanuel
Venue
Ghana Medical Journal
Publisher
African Journals Online (AJOL)
Published
2021-12-01
Volume
55
Issue
4
Pages
298-307
ISSN
0016-9560 (ISSN-L)
DOI
10.4314/gmj.v55i4.11
PMC
PMC9334966
OpenAlex
W4210457303
Cited by
18
References
0
Citations by year
2026: 2 · 2025: 3 · 2024: 10 · 2023: 2 · 2022: 1
FWCI
1.03
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Ghana Medical Journal (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Antibiotic Resistance in Bacteria
  • Health Sciences › Medicine › Epidemiology › Urinary Tract Infections Management
  • Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Antibiotic Use and Resistance
Keywords
extended-spectrum beta-lactamase, Escherichia coli, antimicrobial resistance, blaTEM-1, clinical isolates, prevalence, inpatients versus outpatients, age distribution
MeSH terms
Aged, Anti-Bacterial Agents, beta-Lactamases, Cross-Sectional Studies, Escherichia coli, Escherichia coli Infections, Female, Ghana, Hospitals, Teaching, Humans, Male

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review